Table 2.

Multivariable predictors of treatment resistance in the GDCN and French ANCA vasculitis cohorts^*

	GDCN cohort (n = 331)		French cohort (n = 417)
	OR (95% CI)	P	OR (95% CI)	P
Age, per 10 years	1.21 (1.00–1.47)	0.046	1.32 (1.05–1.66)	0.018
Female vs. male sex	1.84 (1.02–3.33)	0.044	1.06 (0.58–1.94)	0.862
White vs. nonwhite	0.47 (0.20–1.14)	0.097	2.06 (0.26–16.66)	0.498
PR3 ANCA vs. MPO ANCA antibody status†	0.60 (0.31–1.19)	0.144	1.24 (0.49–3.12)	0.650
WG vs. kidney-limited disease (GDCN) or MPA (French)	0.44 (0.11–1.80)	0.253	1.17 (0.41–3.29)	0.773
MPA vs. kidney-limited disease (GDCN)	0.64 (0.26–1.55)	0.318	–	–
Lung involvement	1.89 (0.86–4.17)	0.116	1.25 (0.66–2.37)	0.489
Upper respiratory tract involvement	0.84 (0.38–1.88)	0.675	0.62 (0.30–1.28)	0.191
Skin involvement	0.96 (0.45–2.05)	0.915	0.64 (0.33–1.24)	0.185
Serum creatinine level, per 100 μmoles/liter‡	1.22 (1.12–1.34)	<0.001	1.10 (0.98–1.24)	0.113

^*Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated using logistic regression. Both cohorts were controlled for therapy (cyclophosphamide plus corticosteroids versus corticosteroids alone). GDCN = Glomerular Disease Collaborative Network; WG = Wegener's granulomatosis; MPA = microscopic polyangiitis.

^†The group of patients with proteinase 3 antineutrophil cytoplasmic antibody (PR3 ANCA) included those with PR3 and/or cytoplasmic ANCA; the group of patients with myeloperoxidase (MPO) ANCA included those with MPO and/or perinuclear ANCA.

^‡Level at diagnosis.